Skip to content


Tabrecta, Capmatinib (capmatinib) is a small molecule pharmaceutical. Capmatinib was first approved as Tabrecta on 2008-06-10. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against hepatocyte growth factor receptor. Tabrecta's patents are valid until 2035-07-22 (FDA).
Trade Name Capmatinib
Common Name Capmatinib
Indication breast neoplasms, non-small-cell lung carcinoma
Drug Class Tyrosine kinase inhibitors
Get full access now